AstraZeneca and RQ Biotechnology Sign License Agreement for Monoclonal Antibodies
AstraZeneca has signed a license agreement with RQ Biotechnology for monoclonal antibodies to treat COVID-19.
AstraZeneca has entered into a license agreement with RQ Biotechnology, a company focused on developing treatments and preventative therapies based on mAbs, for early-stage monoclonal antibodies (mAbs) targeted against COVID-19. Under the agreement, AstraZeneca will have an exclusive worldwide license to develop, manufacture, and commercialize mAbs.
RQ Biotechnology specifically focuses on addressing areas of unmet need in vulnerable patient populations through the use of potent broad-spectrum mAbs.
“The COVID-19 pandemic has changed the landscape for immune therapies, including the use of monoclonal antibodies to protect vulnerable patients who can’t respond adequately to vaccination alone,” said Iskra Reic, executive vice president, vaccine & immune therapies, AstraZeneca. “Scientific innovation is rapidly accelerating, and this agreement reflects our continued commitment to the discovery and development of new medicines to help prevent and treat infectious disease, including COVID-19.”
Source: AstraZeneca
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
